New variant MV.1 is spreading quite rapidly, and looks a potential next challenger against the now-dominant DeFLuQE variants (KP.3.1.1 and descendants), perhaps rivalling XEC.
MV.1 first appeared in Maharashtra, India in late June.
🧵
The story might've ended there, but after almost a month the next sample was recorded. It has since spread quite rapidly to 9 countries on 4 continents. Around 40 samples have now been reported.
🧵
In North America, MV.1 has mostly been reported in the north-east US. In Canada; Ontario and BC have reported the first samples.
🧵
In Europe, MV.1 was first reported in Portugal, then Scotland, then Ireland and the Netherlands.
🧵
MV.1 is descended from JN.1.49 by way of MB.1.1.1. That long evolutionary path has been most successful in samples from India, without any notable success elsewhere.
MV.1 reverts the Spike K478T mutation to the ancestral (Wuhan) type.
🧵
Globally, MV.1 is showing a competitive growth advantage of 4.4% per day (31% per week) over JN.1.* + DeFLuQE variants. This is just a shade slower than XEC's current global pace.
🧵
Here's a table of weekly frequencies for MV.1 by geography (continents and/or countries). Note the recent data from India is very thin and lags by many weeks.
🧵
There is apparently very strong growth reported for the US, but the data from the US is often heavily skewed by pooled samples and samples from travellers in the early spread phase of recent variants.
🧵
In this detailed comment, Ryan Hisner highlighted the super-rare nucleotide mutation T29637A, featured in MV.1 ancestor MB.1:
h/t to Variant Hunters and for the tricky GISAID search for MV.1:
C936T,-22995A,T3565C,G7393T
Or
MB.1.1 with -22995A and ORF1a:T224I
🧵x.com/xz_keg x.com/siamosolocani
-22995A means that mutation was reverted back to the ancestral type. In my dataviz, fueled by Nextclade output, -22995A is represented as A22995C.
🧵
As the MV.1 designation has not flowed through into Nextclade, I am approximating it above by searching for it's characteristic mutations.
Interactive mutation matching dataviz, code, acknowledgements and more info here:
Recombinant variant XEC is continuing to spread, and looks a likely challenger against the now-dominant DeFLuQE variants (KP.3.1.1 and descendants).
Here are the leading countries reporting XEC. A chain of samples were reported from Slovenia during August, reaching 12%.
🧵
XEC first appeared in Berlin in late June. It has since spread quite rapidly across Europe, North America and Asia. Around 180 samples have now been reported, from 18 countries on 3 continents. Belgium, Hong Kong and Japan reported their first samples in the last week or so.
🧵
XEC is a mix of KS.1.1 (FLiRT, although XEC did not get the R346T mutation) and KP.3.3 (FLuQE). XEC might have an advantage from it's unusual T22N mutation, in combination with the FLuQE mutations.
🧵
Australia was #1 in the world for median wealth (now #2 by a tiny margin), and well clear of the other anglophone countries. This gives more Australians a relaxed lifestyle, with the freedom to worry less about finances.
🧵 visualcapitalist.com/wp-content/upl…
Policy-wise, I think Australia is leading on the topics of:
- smoking
- drug use
- road safety
- firearms
These seem reflected in (or reflect) differences in general attitudes on these topics, e.g. driving style seems far less aggressive than in other anglo countries.
🧵
Recombinant variant XEC is continuing to spread, and looks a likely next challenger against the now-dominant DeFLuQE variants (KP.3.1.1 and descendants).
🧵
XEC first appeared in Berlin in late June. It has since spread quite rapidly across Europe, North America and Asia.
Around 111 samples have now been reported, from 15 countries on 3 continents. Israel and Spain have reported their first samples in the last week.
🧵
XEC is a mix of KS.1.1 (FLiRT, although XEC did not get the R346T mutation) and KP.3.3 (FLuQE). XEC might have an advantage from it's unusual T22N mutation, in combination with the FLuQE mutations.
🧵
Here's a look at the volume of genomic sequencing data in GISAID, by submission date For 2024. It has been running at 33,000 - 53,000 per month, so over 1,000 per day. July was a relatively high-volume month, and August looks on track to also deliver strong volumes.
🧵
The chart below tracks the median delay between sample collection and submission to GISAID. This is holding steady at 20-30 days.
🧵
Here's a map of the sequences collected in 2024. There are some countries/regions with low/no sequencing data, mostly in Africa and the Middle East. But otherwise there is some coverage from most countries/regions.
🧵
Recombinant variant XEC is continuing to spread very rapidly, and looks a likely next challenger against the now-dominant DeFLuQE variants (KP.3.1.1 and descendants).
🧵
XEC first appeared in Berlin in late June. It has since spread quite rapidly across Europe, North America and Asia. Around 78 samples have now been reported, from 12 countries on 3 continents. Taiwan has reported it's first sample in the last week.
🧵
XEC is a mix of KS.1.1 (FLiRT, although XEC did not get the R346T mutation) and KP.3.3 (FLuQE). XEC might have an advantage from it's unusual T22N mutation, in combination with the FLuQE mutations.
🧵
With DeFLuQE variants dominant or taking over now in most places, it is time to ponder which variant will drive the next wave.
A new leading candidate is recombinant XEC - a potent mix of KS.1.1 (FLiRT) and KP.3.3 (FLuQE).
This first appeared in Berlin in late June.
🧵
Globally, XEC is showing a robust growth advantage of 4.6% per day (32% per week) over JN.1.* + DeFLuQE variants. This is fastest growth of any contender I am aware of. As the starting frequencies are quite low, any crossover looks like happening in September or later.
🧵
Note that as I showed recently, DeFLuQE is showing the strongest recent growth from the Global perspective, and looks poised to take over dominance shortly: